Enhanced MuScreen(TM) Platform Revolutionizes Preclinical Development of Immunotherapeutics
SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced new data further characterizing and enhancing the immunocompetent models included in their large-scale immunotherapy screening platform, MuScreen.
Immunotherapies, alone or in combination with other drugs, treat cancer by modulating the immune system to elicit native antitumor immune responses. To understand response profiles, identify responsive patient populations and/or the opportunities for combination treatments to improve efficacy of immunotherapeutic compounds, researchers need well-characterized, reliable preclinical tools with fully functioning immune systems. CrownBio meets these needs with MuScreen, a large-scale, staggered screening platform that interrogates a panel of commonly used syngeneic tumor models to advance investigations of immuno-oncology agents.
CrownBio's syngeneic models are characterized by immunogenomic (sequencing) data, response to standard of care agents (including checkpoint inhibitor benchmarking) and immunophenotyping (FACS) analysis. MuScreen examines a selection of these well-characterized models and incorporates shared vehicles and common groups in high throughput format to provide reliable results quickly and cost-effectively. MuScreen data is used to rapidly quantify model-specific efficacy, measure resistance, understand pharmacodynamics effects and identify unique combination strategies to guide decision making in immunotherapy development.
"CrownBio is a leading provider of innovative solutions for the discovery and development of immunotherapies," said Dr. Henry Li, CrownBio's Sr. Vice President of Scientific Research and Innovation. "We remain committed to further expanding and characterizing models within the unique MuScreen platform to help our clients navigate their novel immuno-oncology development programs more efficiently."
Learn more about CrownBio's large-scale immunotherapy screening platform, MuScreen, at www.crownbio.com/oncology/immuno-oncology/muscreen.
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Crown Bioscience Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Bermuda Principles event merges science and business20.2.2018 16:36 | Pressemelding
HAMILTON, Bermuda, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Scientists and researchers from around the world are gathering in Bermuda this week for the second edition of a conference exploring the field of genetic research. Premier the Hon David Burt will officially open "Bermuda Principles: Impact on Splicing" Wednesday evening at the Fairmont Southampton. The conference, which runs through Saturday, has registered 50 delegates, along with an impressive roster of 36 speakers and panellists from 11 countries, including Australia, Denmark, Switzerland and South Africa. Among the attendees are prominent geneticists, scientists, professors, researchers, PhD students working in international labs, biotech representatives and investors. "I am elated to see the growth of the conference since last year's event," said Bermudian Dr. Carika Weldon, a biomedical researcher with her own lab at De Montfort University, UK, who conceived of the event and launched it last February. "My main aim has been to p
Globecomm Joins Amazon Web Services Partner Network20.2.2018 16:00 | Pressemelding
Highlights Globecomm establishes direct access to Amazon Web Services (AWS) Direct Connect at key datacenter locations. Customers in U.S. Government, media and entertainment, enterprise video and the Internet of Things (IoT) can interoperate cloud-based services with Globecomm's global satellite and fiber network to reduce capital expenditure and ramp up networks and services faster. Globecomm's suite of Software-as-a-Service (SaaS) applications run on AWS, accessible across both AWS and Globecomm's global network. Globecomm's team in place to design, develop and deliver cloud-centric as well as hybrid architectures for end-to-end services and customer solutions. HAUPPAUGE, N.Y., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Globecomm announced today that it has joined the Amazon Web Services (AWS) Partner Network (APN) as a Standard Technology Partner. This agreement will enable Globecomm to seamlessly interoperate its global satellite and fiber network with AWS's storage, compute and cloud conte
Elite Capital & Co. awarded Infrastructure Project Finance Provider 2018 by New European Economy20.2.2018 15:41 | Pressemelding
LONDON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- The Information Department at Elite Capital & Co. Limited (ECC), announced today that the company features in the specialized and prestigious New European Economy Magazine in its January 2018 issue in Britain and the European Union countries as the "Infrastructure Project Finance Provider 2018". The award is the result of focused efforts and synergy between the ECC Board of Directors and our employees and strategic partners all over the world over the past years. It also reflects the ability of the Company's strategy to adapt to the prevailing global economic circumstances and testifies to the viability of the planning process adopted by the Board of Directors. Dr. Faisal Khazaal, Chairman of Elite Capital & Co. commented on the occasion, "I should thank Mr. George Matharu, President of ECC and his Board Members who make ceaseless efforts towards ensuring that ECC continues to occupy a prestigious position in the field of finance and economy in
New MindManager 11 for Mac: Visually Capture, Organize, and Share Information to Drive Project and Business Success20.2.2018 15:26 | Pressemelding
Powerful mind mapping and information visualization software introduces its most robust Mac version yet; complete with new diagram types, an expanded template library, advanced mapping capabilities, and improved sharing options OTTAWA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Introduced today, MindManager® 11 for Mac brings new elegance and efficiency to the way individuals and teams organize ideas, tackle tasks, and achieve their goals. Already a leader in mind mapping and information visualization on the Mac, MindManager's new release offers advanced mapping capabilities, new diagram types and templates, and easy ways to share and publish your work - all delivered within a redesigned interface optimized to enhance productivity. Individuals, small businesses, and global organizations rely upon MindManager to efficiently brainstorm and organize ideas, communicate knowledge effectively, and execute project success. MindManager enables users to turn unstructured ideas and information into dynam
Ovum Survey Finds NetSfere Among The Top 3 Most Widely Deployed Secure Enterprise Messaging Services20.2.2018 15:00 | Pressemelding
NetSfere is the third most used enterprise platform, clearly outpacing legacy enterprise communication vendors CHICAGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- A report by Ovum, a market-leading research and consulting firm, commissioned by Infinite Convergence Solutions, a global leader in messaging and mobility solutions, finds that within just a few short years of launching, NetSfere is ranked as the third most used enterprise messaging service behind Skype Business and Cisco's Spark. In addition to the need for a secure messaging service, the report shows enterprise demand for communication services that enable collaboration beyond messaging. NetSfere's combined HD voice, video and text capabilities - all preferred means of communication in one encrypted platform - validates its ranking among the top services for enterprises. "With messaging services advancing into all-in-one communications platforms, there's a greater propensity for widespread business use - but also major security risk
Inspiration to Seek Shareholder Approval for Forward Split of its Common Shares20.2.2018 15:00 | Pressemelding
TORONTO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation ("Inspiration" or the "Corporation") (CSE:ISM) would like to announce that, further to its press release dated January 18, 2018, it will be seeking shareholder approval for a special resolution authorizing the directors to effect a forward split of the Corporation's common shares on a one (1) for two (2) basis. As stated in the Corporation's press release of January 18, 2018, Inspiration has scheduled its annual and special meeting of shareholders for May 3, 2018. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, www.inspirationmining.com The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This press release contains forward-looking statements based on assumptions, uncertainties and management's best estimates of future events. Actual results may differ materially from those currently antici
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom